"The U.S. Food and Drug Administration today approved Lymphoseek (technetium Tc 99m tilmanocept) Injection, a radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing "...
- Clinician Information:
Anzemet Injection Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Anzemet Injection (dolasetron mesylate) is an antinauseant and antiemetic used to prevent nausea and vomiting associated with cancer chemotherapy, and to prevent and treat postoperative nausea and/or vomiting. Common side effects include headache, diarrhea, fever, fatigue, abdominal pain, and dizziness.
The recommended intravenous adult dosage of Anzemet Injection is 12.5 mg given as a single dose approximately 15 minutes before the cessation of anesthesia (prevention) or as soon as nausea or vomiting presents (treatment). Pediatric dose is determined by the child's weight. Anzemet Injection may interact with diuretics, anti-arrhythmics, or anthracycline. Tell your doctor all medications and supplements you use. During pregnancy, Anzemet Injection should be used only if prescribed. It is unknown if Anzemet is excreted in human milk. Consult your doctor before breastfeeding.
Our Anzemet Injection (dolasetron mesylate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Anzemet Injection FDA Prescribing Information: Side Effects
In controlled clinical trials, 2265 adult patients received ANZEMET Injection (dolasetron mesylate injection) . The overall adverse event rates were similar with 1.8 mg/kg ANZEMET Injection (dolasetron mesylate injection) and ondansetron or granisetron. Patients were receiving concurrent chemotherapy, predominantly high-dose (≥ 50 mg/m2) cisplatin. Following is a combined listing of all adverse events reported in ≥ 2% of patients in these controlled trials (Table 4).
TABLE 4. ADVERSE EVENTS ≥ 2% FROM CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING STUDIES
|Event|| ANZEMET Injection (dolasetron mesylate injection)
|Hepatic Function Abnorma†||25||(3.6%)||12||(3.4%)|
| *: Ondansetron 32 mg intravenous, granisetron 3 mg intravenous.
† : Includes events coded as SGOT- and/or SGPT-increased (see also Liver and Biliary System below)
In controlled clinical trials with 2550 adult patients, headache and dizziness were reported more frequently with 12.5 mg ANZEMET Injection (dolasetron mesylate injection) than with placebo. Rates of other adverse events were similar. Following is a listing of all adverse events reported in ≥ 2% of patients receiving either placebo or 12.5 mg ANZEMET Injection (dolasetron mesylate injection) for the prevention or treatment of postoperative nausea and vomiting in controlled clinical trials (Table 5).
Table 5. Adverse Events ≥ 2% from Placebo-Controlled Postoperative Nausea and Vomiting Studies
|Event|| ANZEMET Injection (dolasetron mesylate injection)
|Headache||58 (9.4%)||51 (6.9%)|
|Dizziness||34 (5.5%)||23 (3.1%)|
|Drowsiness||15 (2.4%)||18 (2.4%)|
|Pain||15 (2.4%)||21 (2.8%)|
|Urinary Retention||12 (2.0%)||16 (2.2%)|
In clinical trials, the following infrequently reported adverse events, assessed by investigators as treatment-related or causality unknown, occurred following oral or intravenous administration of ANZEMET to adult patients receiving concomitant cancer chemotherapy or surgery:
Cardiovascular: Hypotension; rarely - edema, peripheral edema. The following events also occurred rarely and with a similar frequency as placebo and/or active comparator: Mobitz I AV block, chest pain, orthostatic hypotension, myocardial ischemia, syncope, severe bradycardia, and palpitations. See PRECAUTIONS section for information on potential effects on ECG.
In addition, the following asymptomatic treatment-emergent ECG changes were seen at rates less than or equal to those for active or placebo controls: bradycardia, tachycardia, T wave change, ST-T wave change, sinus arrhythmia, extrasystole (APCs or VPCs), poor R-wave progression, bundle branch block (left and right), nodal arrhythmia, U wave change, atrial flutter/fibrillation.
Furthermore, severe hypotension, bradycardia and syncope have been reported immediately or closely following IV administration.
Dermatologic: Rash, increased sweating.
Hypersensitivity: Rarely - anaphylactic reaction, facial edema, urticaria.
Liver and Biliary System: Transient increases in AST (SGOT) and/or ALT (SGPT) values have been reported as adverse events in less than 1% of adult patients receiving ANZEMET in clinical trials. The increases did not appear to be related to dose or duration of therapy and were not associated with symptomatic hepatic disease. Similar increases were seen with patients receiving active comparator. Rarely - hyperbilirubinemia, increased GGT.
Metabolic and Nutritional: Rarely - alkaline phosphatase increased.
Respiratory System: Rarely - dyspnea, bronchospasm.
Vascular (Extracardiac): Local pain or burning on IV administration; rarely - peripheral ischemia, thrombophlebitis/phlebitis.
There are rare reports of wide complex tachycardia or ventricular tachycardia and of ventricular fibrillation cardiac arrest following intravenous administration.
Read the entire FDA prescribing information for Anzemet Injection (Dolasetron Mesylate Injection) »
Additional Anzemet Injection Information
- Anzemet Injection Drug Interactions Center: dolasetron iv
- Anzemet Injection Side Effects Center
- Anzemet Injection FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.